International Atherosclerosis Society and Pfizer Independent Grants for Learning & Change collaborate on new grant opportunity

PfizerThe International Atherosclerosis Society (IAS) and Pfizer Independent Grants for Learning & Change (IGLC) have announced their collaboration on a new grant opportunity focused on improving care for patients around the world with medium or high levels of cardiovascular risk, with a particular focus on dyslipidemia.

The Request for Proposals (RFP) being issued by both organizations is intended to encourage organizations to submit concepts and ideas for design and implementation of scalable, sustainable programs for healthcare providers and patients in developing countries, designed to improve the management of dyslipidemia and other cardiovascular risk factors.

The IAS is an international federation of 64 national and regional societies whose basic missions are to promote the scientific understanding of the etiology, prevention, and treatment of atherosclerosis. The IAS exists to coordinate the exchange of scientific information among its member societies, to foster research into the development of atherosclerosis and related cardiometabolic diseases, and to help translate this knowledge into improving the effectiveness of programs designed to prevent and treat this disease. As such, the IAS is able to create partnerships worldwide, especially in those areas of the world where the epidemic of atherosclerosis and its related diseases is exploding and thus meet the growing needs in countries in Central and South America, in Eastern Europe, in Africa, in the Gulf Region and in South and South-East Asia.

The mission of the IGLC is to accelerate the adoption of evidence-based innovations that align the mutual interests of patients, healthcare professionals, and Pfizer, through support of independent professional education activities. The term "independent" means the initiatives funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the initiatives, and only asks for reports about the results and impact of the initiatives which it may share publicly.

Comprehensive management of lipids is increasingly recognized as an integral component of cardiovascular risk reduction. However, there remains a wide gap that separates treatment recommendations and real-world lipid management. This is especially evident in economically developing countries.

According to the World Health Organization, cardiovascular disease accounted for nearly 1 of every 3 deaths in 2004, and approximately 80% of these deaths occurred in low- and middle-income countries.[1] In 2010 the Institute of Medicine issued a report, commissioned by the National Heart, Lung, and Blood Institute, to address the increasing burden of cardiovascular disease in developing countries.[2] This report identified numerous barriers to the control of global cardiovascular disease, as well as specific recommendations to increase investment and implementation of cardiovascular disease prevention and management efforts in low- and middle-income countries. Crucial to these efforts are an increased awareness of chronic diseases as a public health priority and coordination among global, national, and regional stakeholders to strengthen healthcare systems.

This RFP is being issued today by both organizations. The IAS is the lead organization for review and evaluation of applications. A review committee, led by the IAS, will ultimately make decisions on which proposals will receive funding. Grant funding will be provided by Pfizer. Collectively, up to $2 million is available for award. Initially, project concepts and ideas must be submitted as "Letters of Intent" to the Pfizer website by the deadline of October 31, 2013 and must be a maximum of 3-pages in length.

Only the member societies of the IAS or their partner organizations may submit Letters of Intent to this RFP. Partnering and collaboration is strongly encouraged.

Organizations interested in responding to this RFP should reach out to the IAS member society in their country or region of the world and submit a collaborative proposal. Similarly, IAS member societies interested in responding to this RFP should bring into their project appropriate partner organizations such as academic medical centers, hospitals or healthcare systems, and other societies or associations.

For further information about the RFP please email This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it. or visit the organization websites below.

For the IAS, please visit the website: http://athero.org

For Pfizer IGLC, please visit the website: http://www.pfizer.com/responsibility/grants_contributions/independent_grants

Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

1. World Health Organization (WHO). Cardiovascular Diseases (CVDs). Fact Sheet No. 317. Geneva, Switzerland: WHO; 2011. http://www.who.int/mediacentre/factsheets/fs317/en/print.html. Accessed May 16, 2012.
2. Institute of Medicine (IOM). Fuster V, Kelly BB eds. Promoting Cardiovascular Health in the Developing World: A Critical Challenge to Achieve Global Health. Washington, DC: National Academies Press; 2010. http://www.nap.edu/catalog.php?record_id=12815. Accessed May 16, 2012.

Most Popular Now

Cannabis extract helps reset brain function in psy…

Research from King's College London has found that a single dose of the cannabis extract cannabidiol can help reduce brain function abnormalities seen in people with psyc...

For first time in 40 years, cure for acute leukemi…

Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemi...

Consuming milk at breakfast lowers blood glucose t…

A change in breakfast routine may provide benefits for the management of type 2 diabetes, according to a new study published in the Journal of Dairy Science. H. Douglas G...

New cancer treatment uses enzymes to boost immune …

Researchers at The University of Texas at Austin have developed a new approach to treating cancer using enzyme therapy. The enzyme, PEG-KYNase, does not directly kill can...

Bayer accelerates six new startups

Changing the experience of health: that's the focus of the six startups which the Bayer G4A team has included in the Accelerator program this year. The young companies fr...

Novartis receives European Commission approval of …

Novartis today announced that the European Commission (EC) has approved Kymriah® (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pe...

Shire completes sale of oncology franchise

Shire plc (LSE: SHP, NASDAQ: SHPG) announces today that it has completed the sale of its Oncology franchise to Servier S.A.S. for $2.4 billion. The franchise includes the...

Bristol-Myers Squibb - Pfizer Alliance ACROPOLIS™ …

The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the pos...

Antioxidant reduces risk for second heart attack, …

Doctors have long known that in the months after a heart attack or stroke, patients are more likely to have another attack or stroke. Now, a paper in the Journal of the A...

SOLAR-1 trial of Novartis investigational alpha-sp…

Novartis today announced the global Phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint s...

Novartis to divest the Sandoz US dermatology busin…

Novartis today announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids po...

New tablet production facility in Ingelheim: Cente…

Boehringer Ingelheim held a groundbreaking ceremony for the construction of a new production facility for innovative drugs. This new Solids Launch facility will focus on ...